2e5 of transient transfected anti-B7-H3 ScFv CAR-293 cells were stained with 0.01ug B7-H3/CD276 Fc Chimera Protein, Human , (Cat. No. UA010607) and Goat Anti-Human IgG, Fcγ Fragment Specific and unrelated protein (Fig. C and B and D), and non-transfected 293 cells were used as a control (Fig. A). Alexa Fluor® 647 signal was used to evaluate the binding activity.
2e5 of transient transfected anti-B7-H3 ScFv CAR-293 cells were stained with isotype and Whitlow/218 Linker-Alexa Fluor® 488 (Fig. F and E). Alexa Fluor® 488 signal was used to evaluate the binding activity.
B7-H3/CD276 Fc Chimera Protein, Human
B7-H3/CD276 Fc Chimera Protein, Human
Price:
Regular price
$400 USD
Regular price
Sale price
$400 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | B7 homolog 3 (B7-H3), CD276, B7 homolog 3 |
| Accession | Q5ZPR3-2 |
| Amino Acid Sequence | Leu29-Pro245, with C-terminal Human IgG1 Fc |
| Expression System | HEK293 |
| Molecular Weight | 60-70kDa |
| Purity | ＞95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | Human Fc Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1. A I Chapoval et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.Nat Immunol. 2001 Mar;2(3):269-74. |
Background
B7 homolog 3 (B7-H3, CD276) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. B7-H3 protein contains two extracellular Ig-like V-type domains and two IgG-like C2-type domains, a transmembrane domain, and a short intracellular domain. Early research examining the biological process of B7-H3 suggested that B7-H3 is a positive regulator of T cell response. Subsequent research studies indicated that B7-H3 is a negative regulator of T cell response, and that the protein inhibits T cell proliferation. One possibility is that B7-H3 interacts with two distinct sets of receptors, resulting in seemingly opposite biological outcomes. B7-H3 is expressed by antigen presenting cells, activated T cells, and a few normal tissues, including placenta and prostate. Expression of B7-H3 is seen in several cancer types, including prostate, breast, colon, lung, and gastric cancers, and in endothelial cells from tumor associated vasculature.
Picture
Picture
FC
SDS-PAGE
1μg (R: reducing conditions, N: non-reducing conditions).
ELISA
Immobilized B7-H3/CD276 Fc Chimera Protein, Human (Cat. No. UA010607) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human B7-H3 (Enoblituzumab) with EC50 of 5.16-8.03ng/mL.
